Clinical Trial Update: Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing SLx-4090 plus statin therapy versus statin alone in reducing LDL-C in patients with hyperlipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• SLx-4090 (SLx-4090)

Snippet

Sponsor: Response Pharmaceuticals | Conditions: Hyperlipidemia | Phase 2 | Status: COMPLETED